Ask about this productRelated genes to: ZNF433 Blocking Peptide
- Gene:
- ZNF433 NIH gene
- Name:
- zinc finger protein 433
- Previous symbol:
- -
- Synonyms:
- FLJ40981
- Chromosome:
- 19p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 2003-04-09
- Date modifiied:
- 2016-10-05
Related products to: ZNF433 Blocking Peptide
Related articles to: ZNF433 Blocking Peptide
- Zinc finger proteins, particularly members of the Krüppel-associated box zinc finger proteins (KRAB-ZFPs), play critical roles in regulating gene expression, cell cycle progression, and epigenetic modifications. Despite the growing body of research on KRAB-ZFPs, the role of ZNF433, a relatively less studied member of this family, remains poorly understood in the context of cancer. - Source: PubMed
Publication date: 2025/06/25
Xie LingyuZeng XinLuo HuiXie BinWang XuefengWu NanZou JunrongZhang GuoxiZou XiaofengXu Hui - An imbalance in the prenatal sex ratio in humans may be due to several factors affecting sperm physiology, including genetic features. In this study, we conducted a transcriptome-wide analysis of expression quantitative trait loci (eQTLs) to identify target genes associated with previously described QTLs associated with gender imbalance. - Source: PubMed
Publication date: 2022/06/09
An YeeunLee Chaeyoung - Clear-cell renal cell carcinoma (ccRCC) is the most common and aggressive form of all urological cancers, with poor prognosis and high mortality. Despite growing evidence of involvement in carcinogenesis, the role of KRAB-ZFP in ccRCC has not been fully explored. KRAB Zinc finger proteins (KRAB-ZFPs) are the largest family of mammalian transcription regulators. They are differentially expressed in various tissues during cellular development and phenotypic differentiation. - Source: PubMed
Heyliger Simone OSoliman Karam F ASaulsbury Marilyn DReams R Renee - Clear-cell renal cell carcinoma (ccRCC) is the most common and aggressive form of all urological cancers, with poor prognosis and high mortality. At late stages, ccRCC is known to be mainly resistant to chemotherapy and radiotherapy. Therefore, it is urgent and necessary to identify biomarkers that can facilitate the early detection of ccRCC in patients. In this study, the levels of transcripts of ccRCC from The Cancer Genome Atlas (TCGA) dataset were used to identify prognostic biomarkers in this disease. Analyzing the data obtained indicated that the KRAB-ZNF protein is significantly suppressed in clear-cell carcinomas. Furthermore, ZNF433 is differentially expressed in ccRCC in a stage- and histological-grade-specific manner. In addition, ZNF433 expression was correlated with metastasis, with greater node involvement associated with lower ZNF433 expression ( < 0.01) and with a more unsatisfactory overall survival outcome (HR, 0.45; 95% CI, 0.33-0.6; = 8.5 × 10). Since ccRCC is characterized by mutations in proteins that alter epigenetic modifications and /or chromatin remodeling, we examined the expression of ZNF433 transcripts in ccRCC with wildtype and mutated forms of BAP1, KDMC5, MTOR, PBRM1, SETD2, and VHL. Analysis revealed that ZNF433 expression was significantly reduced in ccRCC with mutations in the BAP1, SETD2, and KDM5C genes ( < 0.05). In addition, the ZNF433 promoter region was highly methylated, and hypermethylation was significantly associated with mRNA suppression ( < 2.2 × 10). In silico analysis of potential ZNF target genes found that the largest group of target genes are involved in cellular metabolic processes, which incidentally are particularly impaired in ccRCC. It was concluded from this study that gene expression of ZNF433 is associated with cancer progression and poorer prognosis, and that ZNF433 behaves in a manner that suggests that it is a prognostic marker and a possible tumor-suppressor gene in clear-cell renal cell carcinoma. - Source: PubMed
Publication date: 2021/08/12
Heyliger Simone OSoliman Karam F ASaulsbury Marilyn DReams Romonia Renee - Prostate cancer often shows the over-activation of beta-catenin/t-cell factor (TCF) signaling. It remains largely unknown how the beta-catenin/TCF transcriptional machinery is tightly controlled. - Source: PubMed
Publication date: 2019/02/01
Gu ShuoHou PeijinLiu KunNiu XiaobingWei BingjianMao FeiXu Zongyuan